University of Patras
Επίδραση του αυξητικού παράγοντα μετασχηματισμού-β1 (TGF-β1) στην παραγωγή ιντερλευκίνης-6 (IL-6), προσταγλανδίνης (PGE2) και του ενδογενούς αναστολέα των μεταλλοπρωτεϊνασών-1 (ΤΙΜP-1) από ινοβλάστες αρθρικού υμένα και χονδροκύτταρα αρθρικού χόνδρου ασθενών με οστεοαρθρίτιδα: μελέτη της ενδοκυττάριας μεταγωγής σήματος
Abstract
dc:descriptionIn this thesis, the effect of TGF-β1 on the expression and production of IL -6, PGE2 and TIMP-1 by SM fibroblasts and AC chondrocytes was studied, and the signaling pathways that mediate this effect was investigated, in order to elucidate and evaluate of the role eventually played by TGF-β1 in the pathogenesis of OA. It would contribute to the possible choice of the TGF-β1 as a pharmacologic target for the treatment of this disease.Materials and MethodsAll experiments in this study were performed with fibroblast and chondrocytes that were isolated from synovial membrane and articular cartilage, respectively, obtained from patients with Rheumatoid Arthritis or Osteoarthritis undergoing joint arthroplasty. IL-6, PGE2 and ΤΙΜΡ-1 levels in fibroblasts and chondrocytes culture conditioned media were determined by ELISA. The expression of IL-6, COX-1, COX-2, MKP-1, PAI-1, proteasome subunits X, Y, Z, and TGF-β receptors TβRI and TβRII in cells, at mRNA levels, was ascertained by RT-PCR using specific primers.Extracellular signal-regulated kinase (ERK) activation was ascertained by western blot analysis.Reactive oxygen species (ROS) levels, both intracellular and released from cells into the conditioned medium, were determined by fluorometric methods.Results1. Effect of TGF-β1 on PGE2 production by fibroblasts and chondrocytes in cultureTGF-β1 treatment caused a statistically significant increase of PGE2 production from both the fibroblasts and chondrocytes in a dose-dependent fashion, which remained unchanged after culturing for 24 to 48 hours. The TGF-β1-induced production of PGE2 was completely suppressed in the presence of indomethacin (non-specific inhibitor of cyclooxygenases), as well as in the presence of SC-560 (a specific inhibitor of COX-1) or NS-398 (a specific inhibitor of COX-2) in both types of cells.The TGF-β1 was able to induce the expression of the two cyclooxygenases in a time-dependent manner, reaching a maximum at 2h in both types of cells, which was significantly suppressed in the presence either of COX-1 inhibitor, SC-560, or COX-2 inhibitor, NS-398. With the use of the inhibitors of protein kinases, PKA, PKC and tyrosine kinases, H-89, Calphostin C and Genestein, respectively, and the inhibitors of MAP kinases JNK1-3, SP600125, and MEK 1/2, U0126, it was shown that the TGF-β1-induced production of PGE2 in both types of cells, may be implicated the PKC and tyrosine kinases and the MAP kinases JNK and Erk1/2, possibly through activation of the transcription factor AP-1.2. Effect of TGF-b1 on IL-6 production by fibroblasts and chondrocytes in cultureTGF-β1 treatment caused a statistically significant increase in the expression of IL-6 at both protein and mRNA level in in dose-and time-dependent manner, in both types of cells. With the use of the inhibitors of protein kinases, PKA, PKC and tyrosine kinases, H-89, Calphostin C and Genestein, respectively, and the inhibitors of MAP kinases MEK1/2, JNK and p38, U0126, SP60012 5 and SB203580, respectively, it was shown that the TGF-β1- induced expression of IL-6 in both cell types, mainly be implicated the tyrosine kinases and MAP kinases, probably through activation of transcription factor AP-1, and to a lesser extent the PKA and PKC. With time-course experiments and western immunoblotting it was shown that TGF-β1 caused phosphorylation and activation of Erk1/2, reaching a maximum at 5-15 min, followed by being declining until 120min, indicating that Erk1/2 dephosphorylated by the action of a MAP kinases phosphatase, possibly of MKP-1, whose the expression was shown to induce the TGF-β1. The TGF-β1-induced expression of IL-6 in fibroblasts was partially suppressed in the presence of the proteasome inhibitors, MG-132 and Epoxomicin, or the inhibitor of activation of NF-kB, Bay 11-7085, suggesting that the transcription factor NF-kB, probably through its activation via of the ubiquitin / proteasome pathway, is involved in the expression of IL-6, since it was shown that TGF-β1 was able to enhance the expression of all three subunits of the proteasome in SM fibroblasts.The TGF-β1 was also able to induce both the immediate and transient, as well as the slow and sustained production of ROS from SM fibroblasts and AC chondrocytes, by stimulating the expression of an NADPH-oxidase (Nox), which appear to be involved in the expression of IL-6, since it significantly suppressed in the presence of the Nox inhibitor, DPI, or of the antioxidants glutathione (GSH) and N-acetyl-cysteine (NAC), or of the specific scavenger of intracellular ROS, WR -1065.In the TGF-β1-induced expression of IL-6 in SM fibroblasts and AC chondrocytes appears to be involved and PGE2, the production of which is stimulated by TGF-β1, since indomethacin caused partial repression of IL-6 expression by TGF-β1.From all the above factors, involved in the TGF-β1-induced expression of IL-6 in SM fibroblasts, only the protein kinases PKA and PKC, and the JNK MAP kinases appear to be involved in the TGF-β1-induced expression of inhibitor-1 of plasminogen activators (PAI-1), an agent of which the expression is predominantly dependent from TGF-β1 / SMADs pathway, indicating that the induction of the expression of IL-6 and PAI-1 by TGF-β1 is mediated by different signaling pathways.Indeed, the specific inhibitor of SMADs phosphorylation, SB 431542, caused very low suppression on the TGF-β1-induced expression of IL-6 in SM fibroblasts. In contrast, the inhibitors AG 1478 (inhibitor of EGFR activation) and Gleevec (inhibitor of PDGFR activation) caused significant suppression on TGF-β1-induced production of IL-6, indicating the implication of EGFR and PDGFR in the expression of IL-6. Using antibodies against the extracellular portion of EGFR it was shown that the activation of EGFR it is not occurs in an autocrine mode through binding of EGF, whose the production is induced by TGF-β1, to its receptor, but intracellularly in some other way, without the SMADs mediation, likely by direct cross-talking of two receptors or through another intermediary.3. Effect of TGF-β1 on the expression of its receptors TβRI and TβRII in fibroblasts and chondrocytesIt was shown that TGF-β1 was able, through ROS whose the production causes, to induce the expression of TβRII receptor, but not of the TβRI receptor in both cell types. Since TβRII plays the role of the sensor, stimulation of its expression by TGF-b1 enhances the signaling of growth factor.4. Effect of TGF-b1 on TIMP-1 production by fibroblasts in cultureThe TGF-β1 caused a statistically significant increase in the production of TIMP-1 from SM fibroblast in a dose- and time-dependent manner. By the use of the inhibitors of protein kinases, PKA, PKC and tyrosine kinases, H-89, Calphostin C and Genestein, respectively, and the specific inhibitors of MAP kinases, MEK 1/2, and JNK 1-3, U0126, and SP600125, respectively, it was found that only the signaling pathways of PKC and MAP kinases Erk1/2 and JNK may be implicated in the TGF-β1-induced production of TIMP-1 by SM fibroblasts. It was also shown that ROS are involved in TGF-β1-induced production of TIMP-1. The IL-6, although it had the capacity by itself in high concentrations, to induce the expression of TIMP-1, it did not appear to mediate the TGF-β1-induced expression of TIMP-1.ConclusionsTGF-β1 is capable to induce the production of PGE2 from SM fibroblasts and AC chondrocytes. This stimulation is performed via the induction of the expression of both COX-1 and COX-2, which seem to act synergistically. The induction of the expression of COXs by TGF-β1, and therefore the production of PGE2, is performed with the mediation of signaling pathways of PKC and of tyrosine kinases as well as of pathways of MAPK (ERK & JNK) possibly through activation of the transcription factor AP-1.TGF-β1 is capable to induce the production of IL-6 by SM fibroblasts and AC chondrocytes. The TGF-β1 causes both, immediate and slow as well as transient and sustained production of ROS, through the induction of expression of a NADPH-oxidase (Nox), regardless of SMADs, which in turn activate:a) directly or indirectly the EGFR and through of its mediation the pathways of PKC and MAPK / AP-1,b) the transcription factor NF-kB through the pathway of ubiquitin / proteasome and c) the production of PGE2.,These in turn contribute to the induction of IL-6 expression.TGF-β1 autoregulates its activity through the induction of its receptor TβRII expression and through of its ability to induce the expression of MKP-1.TGF-β1 is also capable to induce the production of TIMP-1 by SM fibroblasts. The induction of the expression of TIMP-1 by TGF-β1 appears to take place through a different pathway than that leads to the induction of IL-6 expression.TGF-β1 appears to be a multifunctional growth factor which is able in the same cells to signal simultaneously different pathways which, working together, lead in the expression of different molecules such as PGE2, IL-6, PAI-1 and TIMP-1 in SM fibroblasts. Depending of the type of cells and their origination, TGF-β1 may simultaneously induce multiple signaling pathways and activate a variety of transcription factors (SMADs, AP-1, NF -κB etc.) leading differently in gene expression of various molecules, such as e.g. of IL-6, with the final result every time to be a product of synergism of several factors.For the molecules, whose the expression is induced by TGF-β1, have been established both an anti-inflammatory and a pro-inflammatory role. However, given the fundamental inhibitory role of TGF-β1 upon all cells of both innate and adaptive immunity, the effect of this growth factor in RA and OA probably should not consider only harmful, and its therapeutic blockade should probably never be attempted in patients with RA and OA.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Goura, Sofia
- Γούρα, Σοφία
Subjects
dc:subject × 20- Αυξητικός Παράγοντας Μετασχηματισμού- β1
- Ιντερλευκίνη-6
- Προσταγλανδίνη Ε2
- Ενδογενής αναστολέας των μεταλλοπτωτεϊνασών-1
- Οστεοαρθρίτιδα
- Ρευματοειδής αρθρίτιδα
- Αρθρικός υμένας
- Αρθρικός χόνδρος
- Transforming growth factor β1
- Interleukin-6
- Prostaglandin E2
- Tissue inhibitor of metalloproteinase-1
- Osteoarthritis
- Rheumatoid arthritis
- Synovial membrane
- Articular cartilage
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35377